Dr. Rajeev Saini | Best Medical Oncologists in Jammu - NH

Dr. Rajeev Saini

MD, DNB (Medical Oncology) ECMO Consultant

  • SpecialityMedical Oncology, Oncology

  • HospitalJammu - Shri Mata Vaishno Devi Narayana Multispeciality clinic, Jammu - Shri Mata Vaishno Devi Narayana Superspeciality Hospital

Narayana Health » Jammu » Medical Oncology Oncology » Dr Rajeev Saini

Experience

  • SMVDNSH-11-02-2017 TO Till Date Consultant Medical Oncology

Language Spoken

  • Hindi,English,Dogri

Interests

Affiliations (Professional Memberships) & Certifications

  • J&K Medical Council

Publications

  • Conducted research work with the title “ Study of clinical, biochemical and radiological profile of patients with CNS infection.(MD Thesis)
  • Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11:664.
  • Saini R, Dodagoudar C, Talwar V, Singh S. Malignant ascites with omental metastasis: a rare event in prostate cancer. J Cancer Metastasis Treat. 2015 Apr 15;1:34-5.
  • Saini, R., Batra, U., Jain, A., & Agrawal, C. EGFR mutation--a commonly neglected mutation in squamous cell lung carcinoma. J Cancer Metastasis Treat. 2016 July, 2, 253-254
  • Agrawal C, Kapoor R, Saini R. Rare occurrence of bortezomib-induced Sweet's syndrome in multiple myeloma. International Journal of Health & Allied Sciences. 2016 Jul 1;5(3):178.
  • Saini R, Batra U, Agrawal C, Jain A. To study the epidemiological profile and clinical outcome of advanced non small cell lung carcinoma patients who harbor anaplastic kinase gene rearrangement- A poster presentation at APLCC Chiang Mai, Thailand May 2016.
  • Agrawal C, Saini R, Batra U, Jain A. Study of epidemiological factors, molecular profile and pattern of metastasis of adenocarcinoma lung in Indian female patients- A poster presentation at ACOS New Delhi, India April 2016
  • Conducted research work with the title “a prospective (pilot) study of efficacy and toxicity of perioperative combination therapy (docetaxel, cisplatin, and 5-fluorouracil) (DCF) for locoregionally advanced gastroesophageal and gastric adenocarcinoma”. (DNB thesis)

Do You have a Question?

Enquire Now!